![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Lilly Acquires Chronic Pain Medicine in Potential $950 Million Deal
Lilly Acquires Chronic Pain Medicine in Potential $950 Million Deal
June 4, 2019
Eli Lilly agreed to pay up to $47.5 million up front for Centrexion’s chronic pain treatment currently in Phase I trials.
The deal could be worth up to $575 million if Centrexion’s CNTX-0290 hits its development and regulatory milestones and another $375 million if the drug is approved and reaches certain sales milestones.
CNTX-0290 is a small molecule somatostatin receptor type 4 agonist developed to treat chronic pain—and most important, isn’t an opioid and isn’t addictive.
Upcoming Events
-
21Oct